THE EFFECT OF BLOOD GROUPS ON THE PROGNOSİS OF PATİENTS WİTH COVİD-19

Öz

Abstract Background: Every day we get new information about the Covid-19 disease. This study was conducted to investigate whether the SARS-CoV2 virus has effects on some blood groups and their prognosis. Material-method: Between April and December 2020, 216 patients who were hospitalized and treated were screened. Age, gender, blood groups, length of stay and response to treatment of these patients were examined and the data were evaluated statistically. Results: The mean age of all cases was 61.99±17.42 years, 59.20 ±17.49 years (n: 173, 80.10%) for those who were cured, 73.18±11.84 years for those who died (n: 43) , 19.90%). The hospital stay was found to be 5.98±4.57 days for the patients who died and 10.06±4.86 days for those who were discharged with recovery. The genders were equal. In cases infected with Covid-19 (n:216); we observed that A, B, AB and O blood group rates were 50.9%, 16.7%, 6.5% and 25.9%, respectively. In patients who died; It was found in 35.9%, 18.6%, 7.0% and 34.9%. Conclusion: It was determined that the hospital stay and recovery rates of young patients were better (p<0.05). In other patients, the prognosis worsened with increasing age and shorter hospital stays (p<0.05). When evaluated as a percentage, it was observed that people with A blood group are more susceptible to Covid-19 infection but have a better prognosis and O blood group is less susceptible but have a worse prognosis. No significant correlation was found between death rates and blood groups (p=0.086).

Anahtar Kelimeler

• Key words: Covid-19
• blood type
• prognosis
• healing
• death.

KAN GRUPLARININ COVİD-19 LU HASTALARIN PROGNOZLARI ÜZERİNE OLAN ETKİSİ

Öz

Amaç: Covid-19 hastalığı hakkında her gün yeni yeni bilgiler elde etmekteyiz. Bu çalışmamız SARS-CoV2 virusunun bazı kan gruplarına ve prognozlarına etkileri var mı araştırmak amacıyla yapılmıştır. Materyal -metod: Nisan-Aralık 2020 tarihleri arasında hospitalize edilerek tedavi gören 216 hasta taranmıştır. Bu hastaların yaş, cinsiyet, kan grupları, yatış süreleri ve tedaviye cevapları incelenmiş ve veriler istatistiksel olarak değerlendirilmiştir. Bulgular: Tüm vakaların yaş ortalaması 61,99±17,42 yıl, şifa ile iyileşenlerin 59,20 ±17,49 yıl (n:173, %80,10), ölenlerin 73,18±11,84 yıl (n:43, %19,90) idi. Hastanede kalış süreleri ölen hastaların 5,98±4,57 gün, şifa ile taburcu olanların 10,06±4,86 gün olarak bulundu. Çalışmamızda cinsiyetler birbirine yakın sayıdaydı. Covid-19 ile enfekte (n:216) vakada A; B; AB ve O kan grubu oranları sırasıyla %50,9; %16,7; %6,5 ve %25,9 olduğunu gözledik. Ölen hastalarda ise %35,9; %18,6; %7,0 ve %34,9 oranında bulundu. Sonuç: Genç hastaların hastanede kalma süreleri ve iyileşme oranlarının daha iyi olduğu saptandı (p<0,05). Diğer hastalarda yaş arttıkça ve hastanede kalma süreleri kısaldıkça prognoz kötüleşiyordu (p<0,05). Yüzdesel olarak değerlendirildiğinde, A kan grubuna sahip kişiler Covid-19 enfeksiyonuna daha duyarlı ama prognozları daha iyi ve O kan grubu daha az duyarlı ama prognozları daha kötü olduğu gözlendi. Ölüm oranları ile kan grupları arasında anlamlı bir ilişki saptanmadı (p=0,086). Anahtar kelimeler: Covid-19, kan grubu, prognoz, şifa, ölüm.

Anahtar Kelimeler

• Covid-19
• kan grubu
• prognoz
• şifa
• ölüm.

Kaynakça

1. [1] Kaul D. (2020). An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, epidemiology and clinical implications. Current medicine research and practice, 10(2), 54–64. https://doi.org/10.1016/j.cmrp.2020.04.001
2. [2] Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K., Lau, E., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., … Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine, 382(13), 1199–1207. https://doi.org/10.1056/NEJMoa2001316
3. [3] Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England), 395(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7
4. [4] WHO Covid-19dashboard. Access site https://covid19.who.int, access time: 27.03.2022
5. [5] Fehr, A. R., & Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. Methods in molecular biology (Clifton, N.J.), 1282, 1–23. https://doi.org/10.1007/978-1-4939-2438-7_1
6. [6] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS- CoV-2. Nature microbiology, 5(4), 536–544. https://doi.org/10.1038/s41564-020-0695-z
7. [7] Cooling L. (2015). Blood Groups in Infection and Host Susceptibility. Clinical microbiology reviews, 28(3), 801–870. https://doi.org/10.1128/CMR.00109-14
8. [8] Li, X., Xu, H., & Gao, P. (2018). ABO Blood Group and Diabetes Mellitus Influence the Risk for Pancreatic Cancer in a Population from China. Medical science monitor : international medical journal of experimental and clinical research, 24, 9392–9398. https://doi.org/10.12659/MSM.913769

9. [9] Fan, Q., Zhang, W., Li, B., Li, D. J., Zhang, J., & Zhao, F. (2020). Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan. Frontiers in cellular and infection microbiology, 10, 404. https://doi.org/10.3389/fcimb.2020.00404
10. [10] Hoiland, R. L., Fergusson, N. A., Mitra, A. R., Griesdale, D., Devine, D. V., Stukas, S., Cooper, J., Thiara, S., Foster, D., Chen, L., Lee, A., Conway, E. M., Wellington, C. L., & Sekhon, M. S. (2020). The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID- 19. Blood advances, 4(20), 4981–4989. https://doi.org/10.1182/bloodadvances.2020002623
11. [11] Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., & Tong, S. (2020). Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics, e20200702. https://doi.org/10.1542/peds.2020-0702
12. [12] Kang, S. J., & Jung, S. I. (2020). Age-Related Morbidity and Mortality among Patients with COVID-19. Infection & chemotherapy, 52(2), 154–164. https://doi.org/10.3947/ic.2020.52.2.154
13. [13] Coronavirus (COVID-19), Republic of Korea. Access site: http://ncov.mohw.go.kr/ bdBoardList_Real.do? brdId= 1&brd Gubun= 11&ncvContSeq= &contSeq= &board_id = &gubun=. Data last updated: 2020/12/27, 00:16 pm
14. [14] Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., et al (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ (Clinical research ed.), 368, m1091. https://doi.org/10.1136/bmj.m1091
15. [15] Li, L. Q., Huang, T., Wang, Y. Q., Wang, Z. P., Liang, Y., Huang, T. B., Zhang, H. Y., Sun, W., & Wang, Y. (2020). COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. Journal of medical virology, 92(6), 577–583. https://doi.org/10.1002/jmv.25757
16. [16] Wu, Z., & McGoogan, J. M. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 323(13), 1239–1242. https://doi.org/10.1001/jama.2020.2648
17. [17] Korean Society of Infectious Diseases Korean Society of Pediatric Infectious Diseases Korean Society of Epidemiology Korean Society for Antimicrobial Therapy Korean Society for Healthcare-associated Infection Control and Prevention Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. (2020) 35:e112. 10.3346/jkms.2020.35.e112
18. [18] Jaillon, S., Berthenet, K., & Garlanda, C. (2019). Sexual Dimorphism in Innate Immunity. Clinical reviews in allergy & immunology, 56(3), 308–321. https://doi.org/10.1007/s12016-017-8648-x
19. [19] Eren, C. (2019). Analysis of Distribution of ABO and Rh Blood Groups in İstanbul Province. Dicle Med J (2019) 46 (2) : 241- 246. https://doi.org/10.5798/dicletip.539989
20. [20] Gür, A. , Ekmekyapar, M. & Şahin, L. (2020). The relationship between AB0 blood groups and COVID- 19 . Journal of Surgery and Medicine , 4 (11) , 956-959 . https://doi.org/10.28982/josam.799750
21. [21] Guillon, P., Clément, M., Sébille, V., Rivain, J. G., Chou, C. F., Ruvoën-Clouet, N., & Le Pendu, J. (2008). Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology, 18(12), 1085–1093. https://doi.org/10.1093/glycob/cwn093
22. [22] Latz, C. A., DeCarlo, C., Boitano, L., Png, C., Patell, R., Conrad, M. F., Eagleton, M., & Dua, A. (2020). Blood type and outcomes in patients with COVID-19. Annals of hematology, 99(9), 2113–2118. https://doi.org/10.1007/s00277-020-04169-1
23. [23] Zietz, M., Zucker, J., & Tatonetti, N. P. (2020). Testing the association between blood type and COVID- 19 infection, intubation, and death. medRxiv : the preprint server for health sciences, 2020.04.08.20058073. https://doi.org/10.1101/2020.04.08.20058073
24. [24] Dal, M. S., Ata, N., Altuntaş, F., Başcı, S., Yiğenoğlu, T. N., Korkmaz, S., Namdaroğlu, S., Baştürk, A., Hacıbekiroğlu, T., Doğu, M. H., Berber, İ., Dal, K., Erkurt, M. A., Turgut, B., Çağlayan, M., Imrat, E., Çelik, O., Ülgü, M. M., & Birinci, Ş. (2021). COVID-19 clinical course and blood groups: Turkish population-based study. Turkish journal of medical sciences, 51(4), 1659–1664. https://doi.org/10.3906/sag-2101-321
25. [25] Gündüz M, Temel H. The relationship between the distribution of ABO and Rh blood groups and the clinical course in children with COVID-19. (2021). Health Sciences Journal of Adıyaman University. 2021;7(1):32-37. https://doi.org/10.30569/adiyamansaglik.889914